Key clinical point: An experimental aromatase inhibitor was effective for treating men with hypogonadism while improving semen quality.
Major finding: On the highest tested dose, 90% of patients normalized their testosterone levels and serum concentrations were improved.
Data source: Double-blind randomized multicenter phase 2 trial.
Disclosures: Dr. Jones reported a financial relationship with Mereo BioPharma, the sponsor of this trial.
Jones et al. ENDO 2019, Session OR18-4.